BioSpace News Archive

Encompass Health Corp. announced it will report results for its third quarter ended Sept. 30, 2022, after the market closes on Oct. 26, 2022.

Vanda Pharmaceuticals Inc. and OliPass Corporation announced that they have entered into a research and development collaboration agreement to jointly develop a set of antisense oligonucleotide molecules based on OliPass’ proprietary modified peptide nucleic acids.

Helius Medical Technologies, Inc. announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference, as follows.

The U.S. Food and Drug Administration approved Relyvrio to treat patients with amyotrophic lateral sclerosis, commonly referred to as Lou Gehrig’s disease.

GE Healthcare announced US FDA 510(k) clearance of its breakthrough AIR Recon DL for 3D and PROPELLER imaging sequences.

Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology.

Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced that the Company and Joslin Diabetes Center have entered into a material transfer and collaboration agreement for our Patient Based Ophthalmology Suite, in-home optical coherence tomography device.

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in October.

Join PROMETRIKA and guest Ken Getz, MBA, Executive Director of the Tufts Center for the Study of Drug Development, to explore the ongoing experience with decentralized clinical trials (DCTs).

According to Nova one advisor, the global Cancer Immunotherapy market was valued at USD 82.10 billion in 2021 and it is expected to hit around USD 261.9 billion by 2030 with a CAGR of 13.11% during the forecast period 2022 to 2030.